1. 'Clicking' fragment leads to novel dual-binding cholinesterase inhibitors
- Author
-
Zuzanna Molęda, Anna Zawadzka, Jan K. Maurin, Zbigniew Czarnocki, Armand Budzianowski, Leticia Monjas, Anna K. H. Hirsch, and Chemical Biology 2
- Subjects
Stereochemistry ,medicine.drug_class ,Clinical Biochemistry ,Triazole ,Pharmaceutical Science ,Tryptamine ,Hybrid drugs ,01 natural sciences ,Biochemistry ,Combinatorial libraries ,chemistry.chemical_compound ,Drug Discovery ,Tetrahydroisoquinoline ,medicine ,Animals ,Humans ,Structure–activity relationship ,Horses ,Molecular Biology ,Butyrylcholinesterase ,Cholinesterase ,chemistry.chemical_classification ,Target-guided synthesis ,Dose-Response Relationship, Drug ,Molecular Structure ,biology ,010405 organic chemistry ,Galantamine ,Organic Chemistry ,Active site ,Structure-activity relationship ,0104 chemical sciences ,”click” chemistry ,010404 medicinal & biomolecular chemistry ,Enzyme ,chemistry ,Acetylcholinesterase inhibitor ,Acetylcholinesterase ,biology.protein ,Molecular Medicine ,Click Chemistry ,Cholinesterase Inhibitors - Abstract
Cholinesterase inhibitors are potent therapeutics in the treatment of Alzheimer's disease. Among them, dual binding ligands have recently gained a lot of attention. We discovered novel dual-binding cholinesterase inhibitors, using “clickable” fragments, which bind to either catalytic active site (CAS) or peripheral anionic site (PAS) of the enzyme. Copper(I)-catalyzed azide-alkyne cycloaddition allowed to effectively synthesize a series of final heterodimers, and modeling and kinetic studies confirmed their ability to bind to both CAS and PAS. A potent acetylcholinesterase inhibitor with IC50 = 18 nM (compound 23g) was discovered. A target-guided approach to link fragments by the enzyme itself was tested using butyrylcholinesterase.
- Published
- 2021